Patent · US Active

Humanized anti-CD137 antibodies and uses thereof

US11203643B2 · kind B2 · utility

2Cited by

2References

17Claims

0Family size

Assignee

LYVGEN BIOPHARMA HOLDINGS LIMITED · CN

Inventors

Jieyi Wang · Lake Bluff, US
Yi-Ting Wu · Shanghai, CN

Key dates

Filing date	Mar 19, 2021
Grant date	Dec 21, 2021
Priority date	—
Expiry date	Mar 19, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are humanized anti-CD137 antibodies and methods of using such for eliciting CD137 signaling, thereby enhancing immune responses such as T cell functions. The antibodies disclosed within may be used to treat diseases, such as cancer and immune disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.